Company Description
Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg.
It operates through Contract Manufacturing and Other Nutraceutical Businesses segments. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers.
The Other Nutraceutical Businesses segment distributes healthful nutritional products for sale through mass market, grocery, drug, and vitamin retailers under the Peaceful Sleep and Wheatgrass brands, as well as other branded proprietary nutraceutical products.
This segment also sells private label vitamin and nutritional supplement products through the Internet; provides warehousing and fulfilment services; and distributes fine natural botanicals, including multi minerals, as well as raw materials.
The company was formerly known as Integrated Health Technologies, Inc. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey.
| Country | NJ |
| Founded | 1979 |
| IPO Date | Oct 29, 1996 |
| Industry | Packaged Foods |
| Sector | Consumer Staples |
| Employees | 141 |
| CEO | Ms. Riva Kay Sheppard |
Contact Details
Address: 225 Long Avenue, Building 15 Hillside, New Jersey 07205 United States | |
| Phone | 9739260816 |
| Website | ibiopharma.com |
Stock Details
| Ticker Symbol | INBP |
| Exchange | OTCMKTS |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001016504 |
| CUSIP Number | 45811V105 |
| ISIN Number | US45811V1052 |
| Employer ID | 22-2407475 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Christina Kay | Co-Chief Executive Officer and Director |
| Riva Kay Sheppard | Co-Chief Executive Officer and Director |
| Dina L. Masi | Senior Vice President, Chief Financial Officer and Secretary |
| Jamie E. Levey | Head of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 10, 2024 | 8-K | Current Report |
| May 10, 2024 | 10-Q | Quarterly Report |
| Feb 12, 2024 | 8-K | Current Report |
| Feb 12, 2024 | 10-Q | Quarterly Report |
| Nov 27, 2023 | 8-K | Current Report |
| Nov 16, 2023 | SC 13D | General statement of acquisition of beneficial ownership |
| Nov 14, 2023 | SC 13D | General statement of acquisition of beneficial ownership |
| Nov 9, 2023 | 8-K | Current Report |
| Nov 9, 2023 | 10-Q | Quarterly Report |
| Oct 27, 2023 | DEF 14A | Other definitive proxy statements |